Russell Investments Group Ltd. Acquires New Holdings in Pro-Dex, Inc. (NASDAQ:PDEX)

Russell Investments Group Ltd. bought a new position in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 6,999 shares of the medical instruments supplier's stock, valued at approximately $327,000. Russell Investments Group Ltd. owned about 0.21% of Pro-Dex as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of PDEX. Bank of New York Mellon Corp bought a new stake in Pro-Dex during the 4th quarter valued at approximately $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex in the fourth quarter worth $252,000. Integrated Quantitative Investments LLC bought a new position in shares of Pro-Dex during the fourth quarter worth $254,000. Arrowstreet Capital Limited Partnership purchased a new position in Pro-Dex during the fourth quarter valued at $255,000. Finally, American Century Companies Inc. purchased a new position in Pro-Dex during the fourth quarter valued at $558,000. Institutional investors own 15.28% of the company's stock.

Pro-Dex Price Performance

NASDAQ:PDEX traded down $2.03 during trading hours on Friday, reaching $64.89. The stock had a trading volume of 54,417 shares, compared to its average volume of 25,827. The stock has a market capitalization of $211.61 million, a PE ratio of 32.28 and a beta of 0.40. Pro-Dex, Inc. has a 52 week low of $16.84 and a 52 week high of $70.26. The company has a 50 day moving average price of $49.21 and a two-hundred day moving average price of $44.56. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, sell-side analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Raymond E. Cabillot sold 5,381 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total transaction of $224,064.84. Following the sale, the director now owns 319,752 shares in the company, valued at approximately $13,314,473.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 27,864 shares of company stock worth $1,304,758. 47.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.